L-4-chlorokynurenine · AV-101

What is L-4-chlorokynurenine?

L-4-chlorokynurenine (AV-101) is an orally bioavailable prodrug that crosses the blood-brain barrier and is converted to 7-chlorokynurenic acid, a selective antagonist at the glycine-coagonist site of NMDA receptors. It reduces glutamate excitotoxicity and quinolinic acid synthesis. The drug is studied in Parkinson disease and medication-induced dyskinesia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

AV-101

Drug type

Small molecule

Targets

NMDA receptor glycine-coagonist site (GRIN1)

Mechanism

Antagonist of NMDA receptor glycine-coagonist site (GRIN1)

Pathways

NMDA receptor signaling, glutamate excitotoxicity, quinolinic acid synthesis

Therapy area

Neurology

Developer

VistaGen Therapeutics, Inc. (VTGN)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 2

UNII

77XLH9L40B

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dyskinesia, Medication-InducedHealthyL-Dopa Causing Adverse Effects in Therapeutic UseParkinson Disease

Other drugs acting on GRIN1

More from VistaGen Therapeutics

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT03583554
• ClinicalTrials.gov NCT03583554
• ClinicalTrials.gov NCT04147949

Updated Oct 3, 2026. Something wrong or missing? Report it on the VTGN page.